Psychedelic drugs have been largely misunderstood for years.
However, that’s quickly changing thanks to new evidence from the medical community. The best part – much like cannabis, we could see sizable investments in psychedelics, such as magic mushrooms. All as the global community just begins to support its research. It’s creating sizable opportunity for companies such as Yield Growth Corp. (CSE: BOSS)(OTC: BOSQF).
2020: The Year of Sprouting Mushroom Growth
The global community is just waking up to the opportunity.
in recent months, Johns Hopkins Medicine announced the launch of the Center for Psychedelic and Consciousness Research to study compounds like LSD and psilocybin to treat a range of mental health problems, including anorexia, addiction and depression.
A 2017 study featured in the journal, Nature -- Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms – showed that 47% of treatment-resistant patients with depression showed positive responses five weeks after psilocybin treatments.
Researchers at New York University found psilocybin mushrooms caused a “rapid and sustained” reduction in anxiety and depression in patients with cancer, as reported by the Financial Post. Better, over the last year, Denver, Colorado, and Oakland, California decriminalized the possession of products containing psilocybin or psilocin.
Researchers from the University of California David found that micro-dosing with psychedelic drugs for a prolonged period of time showed promise. “Our study demonstrates that psychedelics can produce beneficial behavioral effects without drastically altering perception, which is a critical step towards producing viable medicines inspired by these compounds," said David Olson of UC Davis, as quoted by Esquire.
Denver became the first city to decriminalize magic mushrooms, as well. All as a “growing body of medical research shows that psilocybin can treat conditions like anxiety and depression, in cases where drugs currently on the market cannot,” as reported by CNN.
Oakland, California followed suit with decriminalization, too.
“Advocates argued that naturally-occurring drugs such as mushrooms and cacti have been used by various cultures for hundreds of years for everything from spiritual quests to helping battle psychiatric imbalances such as post-traumatic stress syndrome,” reported USA Today.
As researchers see further benefits of psilocybin mushrooms for the treatment of mental health issues, it’s already creating sizable investment opportunities.
In short, the mushroom story is only beginning to explode.
Yield Growth Corp. is Rapidly Expanding with Mushrooms
To date, Yield Growth has made substantial headway with the mushroom story.
“We are very excited to be the first publicly traded company to announce a legal path to cultivate and research psychedelic mushrooms,” says Yield Growth and Flourish CEO Penny White. “There is a renaissance of psychedelic medicine for which investor interest could go viral at any time. We are planning to enter this space with first mover advantage to deliver value to our shareholders.”
In late 2019, for example, its subsidiary Flourish Mushroom Labs Inc. completed the acquisition of a catalogue of mushroom formulas as the foundation of a mushroom edibles business. The formulas and know-how acquired relate to formulations that may be used to create ready to eat packaged food products or packaged food products that may be mixed with mushroom varietals of the consumer’s choice.
The formulations include soups, teas, hot cocoa, elixirs and truffles. Flourish has engaged the developers to create additional products to add to the base catalogue and commercialize the formulas, going to market first with mushroom based soups and coffees.
Flourish Mushrooms also entered into an agreement to license 126 formulas based on ancient Ayurvedic medicine to its wholly owned subsidiary Flourish Mushroom Labs for use in products infused with functional or magic mushrooms for a 50 year term.
Flourish Mushrooms Just Appointed its New Chairman of the Board
With sights set on rapidly growing in a $34.4 billion global functional mushroom market, as highlighted by Research and Markets, the company is quickly gaining momentum.
To help increase its market share, the company just appointed Jeff B. Smith, Chairman of the Board, who was an executive for over 20 years at Johnson & Johnson Consumer Companies, the world’s largest and most diversified healthcare company with worldwide sales of US$76 billion in 2017. His roles included Chief Transformation Officer, Group Chairman, Consumer North America and President, U.S. Skincare.
Jeff served on the Johnson & Johnson's Group Operating Committee Executive.
In his role as Johnson & Johnson Company Group Chairman for Consumer North America, Jeff delivered strong organic growth, new growth levers and oversaw several important strategic acquisitions including Vogue International LLC, La Lumière and Neostrata. His division represented more than 42% of global revenue delivering over US$6.5 billion in annual revenue with mid-single digit growth rates; spent over US$1 billion in marketing investment; delivered consistent market share gains and doubled the regional profitability.
Prior to acting as Chairman of Johnson & Johnson, in 2011 Jeff was appointed President, U.S. Skincare in the newly formed North American region. Jeff had full P&L responsibility for the Baby (JOHNSON’S®, AVEENO®) and Beauty Care divisions (NEUTROGENA®, AVEENO®, CLEAN & CLEAR®, LUBRIDERM® and KORRES® Natural products) within the United States.
As President of Johnson & Johnson’s largest business unit, Jeff grew it from the 3rd largest skincare company to #1 in the U.S. over 3.5 years.
The Psychedelic Renaissance Has Only Just Begun
With plenty of research, global support, and legalization of magic mushrooms, the renaissance has only just begun. It’s only a matter of time before we begin to see US FDA approval for such products over the next year.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.